Characteristics of patients initiating treatment with baricitinib and outcomes at follow-up: analysis of BSRBR-RA Registry data
Characteristics of patients initiating treatment with baricitinib and outcomes at follow-up: analysis of BSRBR-RA Registry data
Objectives: to describe selected baseline characteristics, continuation with baricitinib and disease activity over time in patients initiating treatment with baricitinib in a UK real-world rheumatology setting.
Methods: baseline and follow-up data were analysed from baricitinib-treated patients newly recruited to the British Society for Rheumatology Biologics Registry-RA (BSRBR-RA) baricitinib cohort between 1 January 2018 and 31 March 2020. The primary objective was to evaluate continuation of baricitinib treatment in patients with at least one follow-up. Analyses were performed using the full baricitinib cohort, overall and by patient subgroup: biologic DMARD (bDMARD)/targeted synthetic (ts)DMARD-naive vs -experienced, baricitinib 4 vs 2 mg, age ≥65 vs <65 years, monotherapy vs combination therapy and male vs female.
Results: at baseline, the study cohort (n = 561) was 76.5% female, mean age 60.0 years, had longstanding (mean 13.1 years) and severe RA, and 54.0% had previously received a bDMARD/tsDMARD. Of 265 and 110 patients completing the 6- and 12-month follow-ups with available data, 77.7 and 69.1% remained on baricitinib at each time, respectively. In all Kaplan-Meier analyses, >60% of patients remained on baricitinib at 540 days. Continuation of baricitinib therapy differed between some subgroup pairs (bDMARD/tsDMARD naive/experienced, baricitinib 2 mg/4 mg). Disease activity was lower at both follow-ups than at baseline, overall and in all subgroups.
Conclusion: in the early years of real-world baricitinib use in the UK, a high proportion of patients continued with treatment at both 6 and 12 months, at which times disease activity was lower than at baseline.
Humans, Male, Female, Middle Aged, Aged, Arthritis, Rheumatoid/drug therapy, Biological Products/therapeutic use, Routinely Collected Health Data, Treatment Outcome, Antirheumatic Agents/therapeutic use, Biological Factors/therapeutic use
3400-3408
Edwards, Christopher J.
dcb27fec-75ea-4575-a844-3588bcf14106
Mount, Julie
c1e538be-9a36-4264-ad26-12552f10427f
Meeks, Alexandra
236c8717-13e6-4ba0-a21c-f4a3be112218
Gulati, Tania
7de5132a-7d67-41dc-aa39-911b016e1b07
Zaremba-Pechmann, Liliana
b1ed10f7-508e-49ee-b279-08e94f268ce5
Sheesh, Mohamed
d4a4bb56-7a5a-403c-9920-76dd50177e63
Larsson, Esbjörn
068be538-fa65-462b-be66-d656bba29f22
Dennison, Elaine
ee647287-edb4-4392-8361-e59fd505b1d1
3 October 2023
Edwards, Christopher J.
dcb27fec-75ea-4575-a844-3588bcf14106
Mount, Julie
c1e538be-9a36-4264-ad26-12552f10427f
Meeks, Alexandra
236c8717-13e6-4ba0-a21c-f4a3be112218
Gulati, Tania
7de5132a-7d67-41dc-aa39-911b016e1b07
Zaremba-Pechmann, Liliana
b1ed10f7-508e-49ee-b279-08e94f268ce5
Sheesh, Mohamed
d4a4bb56-7a5a-403c-9920-76dd50177e63
Larsson, Esbjörn
068be538-fa65-462b-be66-d656bba29f22
Dennison, Elaine
ee647287-edb4-4392-8361-e59fd505b1d1
Edwards, Christopher J., Mount, Julie, Meeks, Alexandra, Gulati, Tania, Zaremba-Pechmann, Liliana, Sheesh, Mohamed, Larsson, Esbjörn and Dennison, Elaine
(2023)
Characteristics of patients initiating treatment with baricitinib and outcomes at follow-up: analysis of BSRBR-RA Registry data.
Rheumatology (Oxford, England), 62 (10), .
(doi:10.1093/rheumatology/kead074).
Abstract
Objectives: to describe selected baseline characteristics, continuation with baricitinib and disease activity over time in patients initiating treatment with baricitinib in a UK real-world rheumatology setting.
Methods: baseline and follow-up data were analysed from baricitinib-treated patients newly recruited to the British Society for Rheumatology Biologics Registry-RA (BSRBR-RA) baricitinib cohort between 1 January 2018 and 31 March 2020. The primary objective was to evaluate continuation of baricitinib treatment in patients with at least one follow-up. Analyses were performed using the full baricitinib cohort, overall and by patient subgroup: biologic DMARD (bDMARD)/targeted synthetic (ts)DMARD-naive vs -experienced, baricitinib 4 vs 2 mg, age ≥65 vs <65 years, monotherapy vs combination therapy and male vs female.
Results: at baseline, the study cohort (n = 561) was 76.5% female, mean age 60.0 years, had longstanding (mean 13.1 years) and severe RA, and 54.0% had previously received a bDMARD/tsDMARD. Of 265 and 110 patients completing the 6- and 12-month follow-ups with available data, 77.7 and 69.1% remained on baricitinib at each time, respectively. In all Kaplan-Meier analyses, >60% of patients remained on baricitinib at 540 days. Continuation of baricitinib therapy differed between some subgroup pairs (bDMARD/tsDMARD naive/experienced, baricitinib 2 mg/4 mg). Disease activity was lower at both follow-ups than at baseline, overall and in all subgroups.
Conclusion: in the early years of real-world baricitinib use in the UK, a high proportion of patients continued with treatment at both 6 and 12 months, at which times disease activity was lower than at baseline.
Text
kead074
- Version of Record
More information
Accepted/In Press date: 5 February 2023
e-pub ahead of print date: 24 February 2023
Published date: 3 October 2023
Keywords:
Humans, Male, Female, Middle Aged, Aged, Arthritis, Rheumatoid/drug therapy, Biological Products/therapeutic use, Routinely Collected Health Data, Treatment Outcome, Antirheumatic Agents/therapeutic use, Biological Factors/therapeutic use
Identifiers
Local EPrints ID: 487347
URI: http://eprints.soton.ac.uk/id/eprint/487347
ISSN: 1462-0324
PURE UUID: 0d62f65c-4f1e-4c65-893b-7fa94863ffdc
Catalogue record
Date deposited: 19 Feb 2024 20:27
Last modified: 18 Mar 2024 02:42
Export record
Altmetrics
Contributors
Author:
Julie Mount
Author:
Alexandra Meeks
Author:
Tania Gulati
Author:
Liliana Zaremba-Pechmann
Author:
Mohamed Sheesh
Author:
Esbjörn Larsson
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics